CD22 Specific Neutra™ Antibody Products
Product listCD22 is a B-cell specific protein and is maximally expressed on the mature B cells. CD22 was found as an inhibitory component in the B-cell receptor complex. It mediates negative impact on BCR signaling pathway by the tyrosine phosphatase dephosphorylation.
CD22 Ligands
CD22 is a transmembrane protein consists of the cytoplasmic and extracellular portions. The cytoplasmic tail contains an immunoreceptor tyrosine-based inhibitory motifs (ITIM) that inhibit B-cell receptor (BCR)-mediated signaling. The extracellular portion comprises seven Ig-like domains and the first domain is responsible for CD22-ligand binding. On the B-cell surface, CD22 interacts with ligands in cis configuration, while It is in trans configuration on other cells surface or soluble glycoproteins.
BCR signaling
CD22 plays inhibitory and activation role in the BCR signaling. When BCR cross-linking, CD22 is rapidly phosphorylated at tyrosines residues and recruits tyrosine phosphatase SHP-1 to ITIM motifs, resulting in the inhibition of BCR signal. Whereas, the BCR signal will be augmented if other SH2-domain-containing proteins (e.g. Shc, Grb2, SHIP) are recruited to the ITAM motifs after CD22 is phosphorylated.
Fig. 1 The inhibitory and
activation roles of CD22 in BCR signaling.1
Clinical significance
CD22 expression increases progressively along the B cell maturation pathways. CD22 can serve as a good target for therapy of B cell diseases and autoimmune diseases, such as B-lineage acute lymphoblastic lleukemia (B-ALL) and systemic lupus erythematosus (SLE). Currently, CD22 related pathways have been explored in a number of animal models, which suggest that the absence of CD22 contributes to the pathogenesis of autoimmune diseases and B cells have a "hyperactivated" phenotype in the loss of CD22 function. As a immunomodulatory, anti-CD22 antibody epratuzumab has been used in treament for patients with SLE and reduces the disease activity.
Our Product
Creative Biolabs is engaged in the research and development of anti-CD22 antibodies. We offer high-quality antibody products to advance your research.
Fig.
2 ELISA analysis of anti-CD22 Antibody (V3S-1222-YC1463) with human CD22 protein.
Fig.
3 Western blot of anti-CD22 antibody (V3S-1222-YC1463) with human CD22 protein.
Fig.
4 Flow cytometry of anti-CD22 Antibody (V3S-1222-YC1463) with Daudi cell.
REFERENCE
- Walker, J.A.; Smith, K.G.C. CD22: an inhibitory enigma. Immunology. 2008, 123(3): 314-325.
